QUEBEC CITY, Feb. 28, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR)
announced today that it will release its first quarter 2013 results on
March 11, 2013, at 4:00 p.m. (EDT). DiagnoCure's management will host a
conference call the same day, at 4:30 p.m. (EDT). Interested
participants may listen to the call by dialing 1-888-231-8191 or
514-807-9895 and referencing code 11472852 approximately 15 minutes
prior to the call. The Corporation will also provide a live webcast of
the call. Interested participants may access the webcast on
DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations. A replay of the
webcast will be available on DiagnoCure's website for those unable to
participate in the live webcast.
Annual and Special Meeting of Shareholders
DiagnoCure confirms that the Annual and Special Meeting of its
shareholders will be held as follows:
|TIME:||Monday, April 29, 2013|| ||LOCATION: ||McCarthy Tétrault's offices|
||3:00 p.m. (EDT)||
||1000 de la Gauchetière Street West|
||Montréal (Québec) H3B 0A2|
On this occasion, Dr. Yves Fradet, President and Chief Medical Officer,
and Chantal Miklosi, Chief Financial Officer will review the financial
highlights and performance of the Corporation for the fiscal year ended
October 31, 2012.
DiagnoCure (TSX: CUR) is a life sciences corporation that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation had launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license agreement to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic
Gen-Probe, for the development and commercialization of a prostate
cancer test using PCA3, DiagnoCure's proprietary molecular biomarker.
Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe
under CE mark and is approved for commercialization in Canada and the
United States. For more information, visit www.diagnocure.com.
This release contains forwardlooking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forwardlooking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forwardlooking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.